ALKERMES | ALKS - Current Assets


ALKERMES reported $1.93B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Malin Corporation EUR 62.6M 26.7M Dec/2024
Merck USD 47.56B 10.49B Sep/2025
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Otsuka Holdings JPY 1.62T 113.12B Dec/2025
Ovoca Bio EUR 1.56M 3.39M Jun/2025
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025